Health
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV – Press Release – Digital Journal
Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
- Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
- Submission of CVnCoV pre-clinical data package marks start of the rolling process
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 12, 2021 / CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission with the European Medicines Agency (EMA)…
Continue Reading
-
Business22 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick
-
Noosa News24 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
Business23 hours agoDoes Macquarie rate BHP shares a buy after its FY25 results?
-
General18 hours agoMigrants raise concerns over Australia’s English tests for visa applicants